Carlos Alfaro - Concepedia

Author

Carlos Alfaro

Also Known As

Alfaro C, C Alfaro, C Cuchí Alfaro, C. Alfaro, Carlos Alfaro, Carlos Alfaro (108647), Carlos alfaro, Christian Alfaro, T May

147

Publications

5.7K

Citations

H-Index

Concepts

All Affiliations

Universidad de Navarra Clinica Universidad de Navarra Navarre Institute of Health Research Centro de Investigación Biomédica en Red de Cáncer Yale University

About

Carlos Alfaro is an author at Universidad de Navarra specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	13	2.6K
2	Cell Biology	4	4	136
3	Language Studies	1	1	41
4	Classics	1	1	41
5	Clinical Immunology	1	1	54

Carlos Alfaro

Publications

4.9K

Citations

H-Index

Page 1

	Year	Citations
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C Bruno Sangro, Carlos Gómez-Martín, Manuel de la Mata, Journal of Hepatology HepatologyViral HepatitisMedicineImmunologyPathology	2013	977
CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity Álvaro Teijeira, Saray Garasa, María Gato, Immunity InflammationCytokineImmune CytotoxicityGranulocyteImmunology	2020	718
Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients Miguel F. Sanmamed, José Luis Perez‐Gracia, Kurt A. Schalper, Annals of Oncology Cancer ImmunosurveillanceAnti-pd-1 TreatmentMedicineMelanomaImmunology	2017	442
Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs) Carlos Alfaro, Álvaro Teijeira, Carmen Oñate, Clinical Cancer Research	2016	398
Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins Miguel F. Sanmamed, Omar Carranza-Rua, Carlos Alfaro, Clinical Cancer Research	2014	253
Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes Carlos Alfaro, Natalia Suárez, Álvaro González, British Journal of Cancer	2009	208
The HIF-1α Hypoxia Response in Tumor-Infiltrating T Lymphocytes Induces Functional CD137 (4-1BB) for Immunotherapy Asís Palazón, Iván Martínez‐Forero, Álvaro Teijeira, Cancer Discovery	2012	184
Intratumoral Injection of Dendritic Cells Engineered to Secrete Interleukin-12 by Recombinant Adenovirus in Patients With Metastatic Gastrointestinal Carcinomas Guillermo Mazzolini, Carlos Alfaro, Bruno Sangro, Journal of Clinical Oncology	2004	174
Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2−/−IL2Rγnull Immunodeficient Mice Miguel F. Sanmamed, Inmaculada Rodríguez, Kurt A. Schalper, Cancer Research	2015	167
Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients María E. Rodríguez-Ruiz, José Luis Perez‐Gracia, Inmaculada Rodríguez, Annals of Oncology	2018	137

Page 1